Welcome to our dedicated page for Acura Pharm SEC filings (Ticker: ACUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Acura Pharm's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Acura Pharm's regulatory disclosures and financial reporting.
Acura Pharmaceuticals, Inc. reports receiving four additional $100,000 loans from Abuse Deterrent Pharma, LLC between March 30 and May 5, 2026. These loans, together with earlier borrowings under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, bring the principal balance to $10,294,279, with approximately $1,090,000 of accrued interest as of May 5, 2026. The note bears interest at 5.25%, with overdue amounts accruing at 7.5%, and includes events of default such as bankruptcy and failure to pay amounts due.
The funding from AD Pharma is being used for day-to-day operations. Acura states that without additional financing by the end of May 2026, it may need to scale back operations, furlough or lay off employees, or terminate operations and possibly seek bankruptcy protection, which could result in a complete loss of shareholder value. AD Pharma owned approximately 65% of Acura’s outstanding common stock as of April 30, 2026, and holds a warrant for 10.0 million additional shares, while Mr. Schutte directly owned about 13% of the outstanding common stock.
Acura Pharmaceuticals, Inc. notified the SEC it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025 due to liquidity constraints and dependence on loans from Abuse Deterrent Pharma, LLC. The company also states it has not filed Annual Reports for 2022–2024 or any Quarterly Reports for fiscal years 2022–2025. The notification states the registrant has halted its public accounting firm’s review and audit services for prior years pending funding and that no assurance can be given funding or filings will be completed.
Acura Pharmaceuticals reports new related-party financing and mounting liquidity pressure. On February 6, February 13 and March 9, 2026, the company received three loans of $100,000 each from Abuse Deterrent Pharma, LLC under an amended secured promissory note bearing 5.25% interest. Including prior advances, the note’s principal balance is $9,894,279 with about $1,040,000 of accrued interest as of February 28, 2026, and defaulted amounts accrue at 7.5%. The funding supports day-to-day operations, but management warns that without additional financing by the end of March 2026, it may have to scale back, furlough or lay off employees, or terminate operations and potentially seek bankruptcy protection, which could wipe out shareholder value. AD Pharma directly owns roughly 65% of the common stock and holds a warrant for 10 million shares, while its controlling member, Mr. Schutte, directly owns about 13%, highlighting concentrated, related-party control of both equity and debt.
Acura Pharmaceuticals, Inc. received three new $100,000 loans from Abuse Deterrent Pharma, LLC (AD Pharma) on December 31, 2025, January 2, 2026 and January 16, 2026 under its existing secured promissory note. These new advances, together with prior loans and $2,319,279 under the November 10, 2022 amended note, bring total principal to $9,594,279 with approximately $980,000 of accrued interest as of January 15, 2026, bearing interest at 5.25% and 7.5% on overdue amounts. The company states the funding will support day-to-day operations and warns that without additional financing by the end of January 2026 it may have to scale back or terminate operations, furlough or lay off employees, and potentially seek protection under bankruptcy laws, which could result in a complete loss of shareholder value. As of January 15, 2026, AD Pharma owns about 65% of the common stock and holds a warrant for 10.0 million shares, while Mr. Schutte directly owns about 13%.
Acura Pharmaceuticals director Immanuel Thangaraj reported equity compensation activity involving restricted stock units (RSUs) and common stock. On January 2, 2026, 50,000 RSUs previously granted on January 2, 2025 were exchanged on a one-for-one basis into 50,000 shares of common stock, with par value of $0.01 per share paid on exchange. On the same date, he received a new grant of 50,000 RSUs under the 2021 plan, which vest 25% on the last day of each of March, June, September and December 2026, with provisions for immediate vesting upon a change of control and certain other events, and an election to take up to 40% in cash instead of shares. After these transactions, he directly holds 547,647 shares of common stock and 50,000 RSUs, and there are an additional 1,956,396 shares reported as indirectly owned by Essex Woodlands Health Ventures Fund V, L.P., where he is a managing director of the general partner and disclaims beneficial ownership except to the extent of his pecuniary interest.
Acura Pharmaceuticals director William G. Skelly reported equity compensation activity involving restricted stock units and common shares. On January 2, 2026, 50,000 restricted stock units granted on January 2, 2025 were exchanged on a one-for-one basis into 50,000 shares of common stock, with par value of $0.01 per share paid upon exchange. On the same date, Skelly received a new grant of 50,000 restricted stock units under the 2021 plan, which vest 25% on the last day of each of March, June, September and December 2026, with immediate vesting upon a change of control and certain other events. Following these transactions, Skelly beneficially owned 675,989 shares of common stock and 50,000 restricted stock units, all held directly.
Acura Pharmaceuticals director George K. Ross reported equity compensation activity involving restricted stock units (RSUs) and common stock. On January 2, 2026, he acquired 50,000 shares of common stock through an RSU exchange under the 2021 plan, bringing his directly held common stock to 595,903 shares following the transaction.
The filing also shows derivative activity in RSUs. A block of 50,000 RSUs previously granted on January 2, 2025 was exchanged on a one-for-one basis into common stock upon payment of par value of $0.01 per share. In addition, Ross was granted a new award of 50,000 RSUs on January 2, 2026, vesting 25% on the last day of each of March, June, September, and December 2026, with provisions for immediate vesting upon a change of control and certain other events and an election to take up to 40% of the RSUs in cash.